Overview

Empagliflozin and Atrial Fibrillation Treatment

Status:
Not yet recruiting

Trial end date:
2024-04-01

Target enrollment:

Participant gender:

Summary

The primary purpose of this trial is to evaluate the impact of empagliflozin, as compared with placebo, in patients with diabetes mellitus or overweight, heart failure and atrial fibrillation.

Phase:

Phase 4

Details

Lead Sponsor:

Miulli General Hospital

Treatments:

Empagliflozin